ASCO 2020: Key Lung Cancer Studies

CME

Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: September 25, 2020

Expiration: September 24, 2021

Stephen Liu
Stephen Liu, MD
Zofia Piotrowska
Zofia Piotrowska, MD

Activity

Progress
1
Course Completed

In this module, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, discuss key study findings in lung cancers presented at the ASCO 2020 meeting, including results from multiple studies in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with lung cancer do you provide care for in a typical month?

A 66-year-old woman with stage IIIA NSCLC is referred to you for a second opinion. Biomarker testing of her tumor was ordered and revealed an EGFR L858R mutation, and her tumor is deemed completely resectable by a multidisciplinary tumor board.

During your consultation with this patient, which of the following results would you tell them was reported for adjuvant osimertinib following complete tumor resection for patients with early-stage EGFR-mutated NSCLC compared with placebo in an interim analysis of the ADAURA trial?

The phase II DESTINY-Lung01 study evaluated trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody–drug conjugate, in patients with pretreated, advanced NSCLC positive for HER overexpression or a HER2-activating mutation. While discussing the results of this study with a colleague, which of the following toxicities associated with T-DXd therapy in the HER2-mutated cohort would you tell them was most clinically concerning?

Which of the following findings was reported with first-line pembrolizumab plus etoposide and platinum chemotherapy vs placebo plus etoposide and platinum chemotherapy in patients with extensive-stage SCLC in the phase III KEYNOTE-604 trial?